These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16652044)

  • 1. Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.
    Winston A; Patel N; Back D; Khoo S; Bulbeck S; Mandalia S; Pozniak AL; Nelson M; Moyle G; Gazzard B; Boffito M
    J Acquir Immune Defic Syndr; 2006 Apr; 41(5):675-6. PubMed ID: 16652044
    [No Abstract]   [Full Text] [Related]  

  • 2. Virological response to protease inhibitor therapy in an HIV clinic cohort.
    Staszewski S; Miller V; Sabin C; Carlebach A; Berger AM; Weidmann E; Helm EB; Hill A; Phillips A
    AIDS; 1999 Feb; 13(3):367-73. PubMed ID: 10199227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
    Grant P; Taylor J; Cain P; Short W; Gallant J; Farthing C; Thal G; Coakley E; Zolopa A
    Clin Infect Dis; 2009 Mar; 48(5):680-2. PubMed ID: 19191657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
    Lichterfeld M; Wöhrmann A; Schmeisser N; Fätkenheuer G; Salzberger B; Wyen C; Schmitz K; Sauerbruch T; Rockstroh JK
    Eur J Med Res; 2003 Feb; 8(2):56-60. PubMed ID: 12626282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Synthetic HIV proteinase inhibitors and new prospects for drug therapy of HIV infections and AIDS].
    Galegov GA
    Vopr Virusol; 1997; 42(6):284-6. PubMed ID: 9499245
    [No Abstract]   [Full Text] [Related]  

  • 6. The daunting challenge of keeping HIV suppressed.
    Cohen J
    Science; 1997 Jul; 277(5322):32-3. PubMed ID: 9229768
    [No Abstract]   [Full Text] [Related]  

  • 7. Hydroxyurea in HIV therapy.
    HIV Hotline; 1998 Mar; 8(1):5-7. PubMed ID: 11365359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden.
    Häggblom A; Svedhem V; Singh K; Sönnerborg A; Neogi U
    Lancet HIV; 2016 Apr; 3(4):e166-74. PubMed ID: 27036992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the principles of anti-HIV drug therapy.
    Horn T
    Surviv News (Atlanta Ga); 2001 Jul; ():13. PubMed ID: 11683014
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy.
    Barreiro PM; Dona MC; Castilla J; Soriano V
    AIDS; 1999 Mar; 13(4):525-6. PubMed ID: 10197384
    [No Abstract]   [Full Text] [Related]  

  • 12. What's new in HIV.
    Morris-Jones S; Nelson MR
    J Infect; 1999 Mar; 38(2):i-ii. PubMed ID: 10342641
    [No Abstract]   [Full Text] [Related]  

  • 13. Higher antiviral activity of antiretroviral regimens including protease inhibitors.
    de Mendoza C; Soriano V; Rodríguez-Rosado R; González-Lahoz J
    AIDS; 1999 May; 13(8):998-9. PubMed ID: 10371186
    [No Abstract]   [Full Text] [Related]  

  • 14. Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome.
    Valdez H; Lederman MM; Woolley I; Walker CJ; Vernon LT; Hise A; Gripshover BM
    Arch Intern Med; 1999 Aug 9-23; 159(15):1771-6. PubMed ID: 10448781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression.
    Chan-Tack KM; Edozien A
    J Acquir Immune Defic Syndr; 2006 Apr; 41(4):531-2. PubMed ID: 16652066
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-HIV agents. Nelfinavir levels during pregnancy.
    TreatmentUpdate; 2004; 16(3):5-6. PubMed ID: 17216835
    [No Abstract]   [Full Text] [Related]  

  • 17. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching meds: from protease inhibitors to non-nukes.
    TreatmentUpdate; 2001; 12(10):1-2. PubMed ID: 11570061
    [No Abstract]   [Full Text] [Related]  

  • 20. Indinavir: lightening the load.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1996 Aug; 2(8):6-11. PubMed ID: 11363759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.